10-Q: BioCardia Reports Q1 2024 Results, Faces Going Concern Uncertainty Amidst Ongoing Clinical Trials

BioCardia's Q1 2024 results show a net loss of $2.267 million and raise concerns about the company's ability to continue as a going concern without additional funding.

Summary

• BioCardia, a clinical-stage company, reported a net loss of $2.267 million for the first quarter of 2024, compared to a net loss of $3.501 million for the same period in 2023.
• The company's revenue decreased to $55,000 from $64,000 year-over-year.
• Research and development expenses decreased to $1.241 million from $2.384 million year-over-year, primarily due to clinical staff reductions.
• Selling, general, and administrative expenses also decreased to $1.089 million from $1.190 million year-over-year.
• As of March 31, 2024, BioCardia had cash and cash equivalents of $949,000.
• Management believes that the current cash balance is insufficient to fund operations beyond June 2024, raising substantial doubt about the company's ability to continue as a going concern.
• The company is actively pursuing additional funding through various means, including debt and equity arrangements.
• BioCardia is advancing multiple clinical trials, including the CardiAMP autologous cell therapy trials for ischemic heart failure and chronic myocardial ischemia, and the CardiALLO allogeneic cell therapy trial for heart failure.
• The company is also developing the Helix biotherapeutic delivery system and Morph steerable introducer platform.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges and going concern uncertainty, overshadowing positive clinical trial developments. The need for immediate capital raises and the risk of Nasdaq delisting contribute to a negative sentiment.

Positives

• The net loss decreased year-over-year, indicating improved cost management.
• Research and development expenses decreased significantly, reflecting the completion of enrollment in the CardiAMP Heart Failure Trial.
• The CardiAMP Heart Failure Trial showed promising results, particularly in a subgroup of patients with elevated NTproBNP.
• The CardiAMP Cell Therapy Heart Failure II Trial was activated, marking progress in the company's clinical development.
• The CardiALLO allogeneic MSC trial has shown no adverse events in its initial cohort.
• The company has secured a biotherapeutic delivery partnership with StemCardia.
• The Morph-DNA product family is on track for FDA submission, potentially opening new revenue streams.

Negatives

• The company's revenue decreased slightly year-over-year.
• The company has a limited cash balance of $949,000 as of March 31, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern beyond June 2024 without additional funding.
• The company is not in compliance with Nasdaq listing requirements and faces potential delisting if compliance is not regained by September 2, 2024.

Risks

• The company's limited cash reserves raise significant concerns about its ability to fund operations beyond June 2024.
• The company's ability to continue as a going concern is dependent on securing additional funding, which is not guaranteed.
• Failure to regain compliance with Nasdaq listing requirements could lead to delisting and negatively impact the company's share price and ability to raise capital.
• The company's clinical trials are subject to risks, including delays, unexpected results, and regulatory hurdles.
• The company's revenue is inconsistent and dependent on partners' development activities.
• The company faces competition in the development of cell therapies and biotherapeutic delivery systems.

Future Outlook

BioCardia plans to raise additional capital to fund its operations and continue the development of its therapeutic candidates. The company expects to complete follow-up in the CardiAMP HF trial and prepare the dataset for potential submission to Japan PMDA. The company also anticipates completing enrollment in the Phase I CardiALLO trial as early as the end of 2024, with Phase II development to follow.

Management Comments

• Management expects operating losses and negative cash flows to continue through at least the next several years.
• Management believes cash and cash equivalents of $949,000 as of March 31, 2024 are not sufficient to fund our planned expenditures and meet our obligations beyond June 2024.
• Management plans to raise additional capital, potentially including debt and equity arrangements, to finance future operations.
• Management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring.

Industry Context

BioCardia operates in the competitive field of cell therapy and biotherapeutic delivery. The company's focus on cardiovascular and pulmonary diseases aligns with significant unmet medical needs. The partnerships with other companies and academic institutions are a common strategy in the biotech industry to share development costs and expand market reach. The company's challenges in securing funding and maintaining Nasdaq listing are not uncommon for clinical-stage biotech companies.

Comparison to Industry Standards

• BioCardia's cash burn rate is typical for a clinical-stage biotech company, but the current cash balance is concerning compared to industry benchmarks.
• The company's reliance on external funding is common in the biotech sector, but the uncertainty around securing additional capital is a significant risk.
• The clinical trial results for CardiAMP show promise, but the company needs to demonstrate consistent efficacy and safety to compete with other cell therapy developers.
• The partnership with StemCardia is a positive step, but the company needs to secure more such collaborations to diversify its revenue streams.
• The development of the Morph-DNA platform is a strategic move to expand into new markets, but the company needs to secure FDA approval and demonstrate market demand.
• Companies like Mesoblast and Athersys are also developing cell therapies for similar indications, and BioCardia needs to differentiate itself through clinical results and commercialization strategies.
• The company's challenges with Nasdaq listing compliance are not unique, as many small-cap biotech companies face similar hurdles.

Related Party Transactions

• The company has a related party payable for discounts owed to BSLF, L.L.C., an entity owned and controlled by Andrew Blank, Chair of BioCardia's board of directors.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential delisting from Nasdaq.
• Employees may be affected by potential cost-cutting measures or restructuring if the company fails to secure additional funding.
• Customers and partners may be concerned about the company's ability to continue operations and fulfill its obligations.
• Creditors face increased risk of non-payment if the company's financial situation does not improve.

Next Steps

• BioCardia will seek to raise additional capital to fund operations beyond June 2024.
• The company will work to regain compliance with Nasdaq listing requirements by September 2, 2024.
• The company will complete follow-up in the CardiAMP HF trial and prepare the dataset for potential submission to Japan PMDA.
• The company will continue enrollment in the CardiAMP Cell Therapy Heart Failure II Trial.
• The company will continue the CardiALLO allogeneic MSC trial and seek funding for later development.
• The company will submit the Morph-DNA product family for FDA approval in the second quarter of 2024.
• The company will present results from the Excellent Phase 1/2b cell therapy study at the European Society of Cardiology Heart Failure Congress.

Key Dates

Keywords

BioCardia, Cell Therapy, Cardiovascular Disease, Heart Failure, Clinical Trials, Biotherapeutic Delivery, Going Concern, Funding, Nasdaq, HFrEF, Refractory Angina, MSC, Helix, Morph